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Dislipoproteinemia is the risk factor of coronary heart disease and other diseases, conditioned by atherosclerosis. That`s why medicinal correction is important for practical cardiology. Due to present conception, inhibitors of GOMK-reductase (statines) are the necessary chain in coronary heart disease, complicated by chronic cardiac failure.
Results of great number of multicenter researches during the last 15 years are evidence of statines efficiency (WOSCOP, MAAS, MARS, AFCAPS, 4S researches). It was proved that regular usage of statines leads to decrease of frequency of myocardium infarction development and death caused by coronary vessels pathology on 40%.    
The object of our research was to study lovastatin influence on indexes of lipid metabolism and clinical course of concomitant chronic cardiac failure and type II diabetes patients. 
Materials and Methods. We observed 47 patients with type II diabetes, cardiac heart (CHD) complicated by chronic cardiac failure in age from 67 to 87 years (27 men and 20 women). Lovastatin was prescribed side by side with basic therapy in dose 20 mg one time a day in the evening white eating. Each patient was examined before treatment and in three weeks of lovastatin intake 38 patients were examined for the second time in 6 months after discharge from the hospital. Each of them confirmed that they had taken lovastatin regularly. Control group included 15 patients with CHD complicated by chronic cardiac failure without type II diabetes.
Side-effects development, lovastatin influence on biochemical indexes and blood cells were estimated in our research. Side-effects were noted at 4 patients of 47: abdominal pain and dry mouth. Lovastatin influence on bilirubin, creatinin, urea haemoglobin levels, ESR, content of leucocytes and erythrocytes in blood. Clinical tolerance to lovastatin was satisfactory.
Conclusion. Conducted research showed that prolonged course of treatment by lovastatin during 6 months at patients with CHD, complicated by CF at type 2 diabetes was accompanied by reliable decrease of level of general cholesterol (on 15,74%) and triglycerides (on 17,92%). Lovastatin shows antiishemic effect at patients with CHD and diabetes mellitus of the II type, which is conditioned by direct influence on lipid exchange and also by endothelium protector effect. Even after therapy by lovastatin in dose 20 mg a day during 3 weeks tendency to decrease of number or CHD attacks and to increase of tolerance to physical loading at patients with chronic cardiac failure and type 2 diabetes was noted, at conducting of 6-minutes walk test prevalence of normotonic reaction after treatment in comparison with results before treatment. Lovastatin is characterized by high tolerance by the patients with chronic cardiac failure and type 2 diabetes, it almost doesn’t cause side effects and complications. 



